SE8901115L - Biologiskt aktiva proteiner - Google Patents

Biologiskt aktiva proteiner

Info

Publication number
SE8901115L
SE8901115L SE8901115A SE8901115A SE8901115L SE 8901115 L SE8901115 L SE 8901115L SE 8901115 A SE8901115 A SE 8901115A SE 8901115 A SE8901115 A SE 8901115A SE 8901115 L SE8901115 L SE 8901115L
Authority
SE
Sweden
Prior art keywords
biologically active
active proteins
proteins
febule
tnf
Prior art date
Application number
SE8901115A
Other languages
Unknown language ( )
English (en)
Swedish (sv)
Other versions
SE8901115D0 (sv
Inventor
J-M Dayer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8901115D0 publication Critical patent/SE8901115D0/xx
Publication of SE8901115L publication Critical patent/SE8901115L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8901115A 1988-03-31 1989-03-30 Biologiskt aktiva proteiner SE8901115L (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888807803A GB8807803D0 (en) 1988-03-31 1988-03-31 Biochemical product

Publications (2)

Publication Number Publication Date
SE8901115D0 SE8901115D0 (sv) 1989-03-30
SE8901115L true SE8901115L (sv) 1989-10-01

Family

ID=10634493

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8901115A SE8901115L (sv) 1988-03-31 1989-03-30 Biologiskt aktiva proteiner

Country Status (12)

Country Link
JP (1) JPH02117700A (da)
KR (1) KR890014125A (da)
AU (1) AU3228789A (da)
BE (1) BE1001845A4 (da)
DE (1) DE3910323A1 (da)
DK (1) DK156589A (da)
FR (1) FR2629345A1 (da)
GB (2) GB8807803D0 (da)
IL (1) IL89804A0 (da)
IT (1) IT1232827B (da)
NL (1) NL8900779A (da)
SE (1) SE8901115L (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1991003553A1 (en) * 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992001002A1 (en) * 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
US5304634A (en) * 1990-10-12 1994-04-19 Hoechst Aktiengesellschaft Inhibitors for the formation of tumor necrosis factor
ES2145744T5 (es) * 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
WO1993004375A1 (en) * 1991-08-23 1993-03-04 Nchip, Inc. Burn-in technologies for unpackaged integrated circuits
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis

Also Published As

Publication number Publication date
IT8947794A0 (it) 1989-03-30
FR2629345A1 (fr) 1989-10-06
DK156589A (da) 1989-10-01
SE8901115D0 (sv) 1989-03-30
DE3910323A1 (de) 1989-10-19
IT1232827B (it) 1992-03-05
NL8900779A (nl) 1989-10-16
AU3228789A (en) 1989-10-05
IL89804A0 (en) 1989-09-28
GB2218101A (en) 1989-11-08
KR890014125A (ko) 1989-10-21
JPH02117700A (ja) 1990-05-02
BE1001845A4 (fr) 1990-03-20
GB8807803D0 (en) 1988-05-05
DK156589D0 (da) 1989-03-30
GB8907148D0 (en) 1989-05-10

Similar Documents

Publication Publication Date Title
SE8901115D0 (sv) Biologiskt aktiva proteiner
IT1182721B (it) Procedimento di purificazione di proteine ossee
ATE70718T1 (de) Pharmakadepotpraeparat.
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69008423D1 (de) Dynamische Fixierung von Schweinsaortaklappen.
MY102472A (en) Preparation of funtional human urokinase proteins.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3581407D1 (de) Bewahrung lebender gewebe.
DK430486A (da) Fremgangsmaade til udvinding af protein
DK235687D0 (da) Tilberedninger til syntese af prostaglandiner og hydroxyfedtsyrer i biologiske systemer og anvendelse deraf
DE69822164D1 (de) Verfahren zur identifizierung von verbindungen mit verminderter systemischer aktivität
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
DE68917324D1 (de) Methode zur Immobilisierung von physiologisch aktiven Substanzen.
KR900002795A (ko) 하이브리드 단백질c 작제물 및 그들의 제조방법
FI875518L (fi) Menetelmä kudosproteiini PP4:n puhdistamiseksi
BG50159A3 (bg) Метод за получаване на производни на пиранобензоксадиазол
DK109590D0 (da) Biologisk aktivt protein
NO864301D0 (no) Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser.
EP0239644A4 (en) NEW PHYSIOLOGICALLY ACTIVE AGENTS WITH A BLOOD COAGULATING REGULATORY EFFECT.
DE3883044D1 (de) Wirkstoff zur tumorbekaempfung.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE3855007D1 (de) METHODE ZUR REINIGUNG REKOMBINANTER t-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN
DE3874034D1 (de) Reinigung von gm-csf.
IT8719420A0 (it) Purificazione di interleuchina-1umana ricombinante.
KR870004142A (ko) 인터로이킨-2 유도체의 제조방법

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8901115-9

Effective date: 19910424